{"id":2567,"date":"2016-04-12T14:06:32","date_gmt":"2016-04-12T18:06:32","guid":{"rendered":"https:\/\/medicarereport.org\/?p=2567"},"modified":"2016-04-12T14:35:13","modified_gmt":"2016-04-12T18:35:13","slug":"medicare-spends-20-9-billion-on-part-b-drugs-in-2013","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=2567","title":{"rendered":"Medicare Spent $20.9 Billion on Part B Drugs in 2013"},"content":{"rendered":"

In 2013, Medicare spent $20.9 billion on Part B drugs which particular 9 drugs accounted for 76% of the total Part B drug costs. One drug (Soliris, Alexion Pharmaceuticals) alone cost $340,500 per beneficiary \u2013 only 441 beneficiaries received this drug in 2013.<\/p>\n

The nine drugs are:<\/p>\n

    \n
  1. Lucentis: $1.37 billion<\/li>\n
  2. Eylea: $1.09 billion<\/li>\n
  3. Prolia: $665 million<\/li>\n
  4. Treanda: $332 million<\/li>\n
  5. Lexiscan: $257 million<\/li>\n
  6. Yervoy: $224 million<\/li>\n
  7. Privigen: $184 million<\/li>\n
  8. Provenge: $183 million<\/li>\n
  9. Soliris: $150 million<\/li>\n<\/ol>\n

    Source: U.S Government Accountability Office<\/p>\n

    Why this should concern seniors, because if the individual\u2019s medical coverage does not have an annual out-of-pocket limit, it would be extremely costly for the Medicare patient. Read article here\u2026..<\/a><\/p>\n

    <\/pre>\n
    \u00a0<\/span>Notice<\/strong>: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n
     <\/p>\n
     <\/p>\n","protected":false},"excerpt":{"rendered":"
    In 2013, Medicare spent $20.9 billion on Part B drugs which particular 9 drugs accounted for 76% of the total<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6,15],"tags":[],"class_list":["post-2567","post","type-post","status-publish","format-standard","hentry","category-medicare-general","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/2567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2567"}],"version-history":[{"count":2,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/2567\/revisions"}],"predecessor-version":[{"id":2569,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/2567\/revisions\/2569"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}